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VIP treatment prevents embryo 
resorption by modulating 
efferocytosis and activation profile 
of maternal macrophages in the 
CBAxDBA resorption prone model
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Mónica Vermeulen2, Claudia Pérez Leirós1 & Rosanna Ramhorst1
Successful embryo implantation occurs followed by a local pro-inflammatory response subsequently 
shifted toward a tolerogenic one. VIP (vasoactive intestinal peptide) has embryotrofic, anti-
inflammatory and tolerogenic effects. In this sense, we investigated whether the in vivo treatment 
with VIP contributes to an immunosuppressant local microenvironment associated with an improved 
pregnancy outcome in the CBA/J × DBA/2 resorption prone model. Pregnancy induced the expression 
of VIP, VPAC1 and VPAC2 in the uterus from CBA/J × DBA/2 mating females on day 8.5 of gestation 
compared with non-pregnant mice. VIP treatment (2 nmol/mouse i.p.) on day 6.5 significantly increased 
the number of viable implantation sites and improved the asymmetric distribution of implanted 
embryos. This effect was accompanied by a decrease in RORγt and an increase in TGF-β and PPARγ 
expression at the implantation sites. Moreover, VIP modulated the maternal peritoneal macrophages 
efferocytosis ability, tested using latex beads-FITC or apoptotic thymocytes, displaying an increased 
frequency of IL-10-producer F4/80 cells while did not modulate TNF-α and IL-12 secretion. The 
present data suggest that VIP treatment increases the number of viable embryos associated with an 
increase in the efferocytic ability of maternal macrophages which is related to an immunosuppressant 
microenvironment.
From the perspective of the immune system, pregnancy involves the generation of a sterile inflammatory response 
that will be physiologically limited in its extent and duration by several immunoregulatory mechanisms1,2. This 
pro-inflammatory response is accompanied by tissue remodeling at the implantation site, associated with apoptosis 
processes that generate a cell turn over implicated in the maintenance of tissue homeostasis and allowing tropho-
blast invasion into maternal decidua3,4. Maternal immune system had to evolve mechanisms for tissue homeostasis 
maintenance in a tolerogenic microenvironment including the participation of specialized leukocyte subpopula-
tions, such as regulatory T cells (Treg), uterine NK cells, decidual macrophages activated in an alternative profile 
and tolerogenic dendritic cells5–7 as well as various cytokines, chemokines, galectins and immune polypeptides8,9.
In this sense, the specialized Treg population (CD4 + CD25 + Foxp3+ ), essential for maternal tolerance of 
the conceptus, is stimulated through antigen-specific and antigen non-specific pathways thus exerting their sup-
pressive actions in the critical peri-implantation phase of pregnancy10. This local tolerogenic microenvironment 
is also accompanied by a decrease in T-bet (transcriptor factor associated with a Th1 profile) and RORγ t expres-
sion (transcription factor associated with a Th17 profile) in several ex vivo and mice models11–15. In humans, low 
frequency of Th17 cells was reported in the decidua in comparison to blood during early pregnancy13,16; and also 
a systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells13.
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Consistently with a tolerogenic microenvironment, maternal macrophages present a predominant alternative 
activation profile contributing to the production of IL-10 and TGFβ , wound healing mediators synthesis and the 
clearance of apoptotic bodies5,17. In this sense, the efferocytosis, or engulfment of apoptotic cells by macrophages, 
is an essential process that contributes to tissue homeostasis with a profound influence on inflammation resolution, 
through secretion of anti-inflammatory cytokines, such as TGF-β and IL-105,17,18.
In this intricate network generated by maternal leukocytes at the maternal-placental interface, the role of the 
immune peptides is to allow the communication between immune and trophoblast cells8.
Particularly VIP, vasoactive intestinal peptide, mediates immune and nervous effector functions and 
has emerged as a potential effective treatment for inflammatory and autoimmune disorders based on its 
anti-inflammatory and tolerogenic effects11,18,19 as it was demonstrated in mouse models of inflammation through 
its action on macrophages and T cell VPAC receptors20–22.
In the feto-maternal context, VIP is present in viable implantation sites of normal mice where it induces an 
increase in Treg frequency12. However, lower levels of VIP and Foxp3 were found in implantation sites of predi-
abetic NOD (non-obese diabetic) mice, which are characterized by a Th1 systemic cytokine profile, correlating 
with a reduction in litter size and increased resorption rates23. In fact, pregnant NOD mice treated with VIP at 
gestational day 6.5, show a modulation of inflammatory signals at the early maternal-fetal interface and a partial 
improvement in the pregnancy outcome12.
Since the control of the initial inflammatory response after embryo implantation is crucial for a successful 
pregnancy outcome1,2 and considering that VIP mediates anti-inflammatory and tolerogenic immune effects, we 
hypothesized that VIP participates in homeostasis maintenance at the early maternal-placental interface inducing 
an immunosuppresant microenvironment through maternal macrophage efferocytosis associated with an alter-
native activation profile. The mating of CBA/J females (H2k) with DBA/2 males (H2d) provokes spontaneously 
high resorption rates associated with a failure in the maternal tolerogenic response, whereas mating CBA/J females 
with BALB/c mice, which also bear H2d antigens, ends in completely normal pregnancies offering the possibility 
to elucidate immunological mechanisms and modify them through different drug treatments24. In line with this, 
we propose that VIP treatment at the early post implantation window of pregnant CBA/J × DBA/2 mouse mating, 
would induce an immunosuppressant local microenvironment that could contribute to reach certain end-points 
of normal gestation, such as the number of viable embryo and a symmetric distribution along the uterine horns.
Results
VIP/VPAC system expression at the feto-maternal interface in CBA/J × DBA/2 matings: char-
acterization in viable implantation sites. CBA/J × DBA/2 mating is a well-studied model of immuno-
logically mediated peri-implantation pregnancy loss that shares features with human pregnancy complications. 
Embryos derived from mating CBA/J females with DBA/2 males showed an increased frequency of resorption 
rates compared with other strains or strain combinations25,26. Embryonic lethality in this mating is due to the 
rejection of the semiallogeneic placenta by several altered maternal immune mechanisms, such as a reduction in 
Treg frequency24.
First of all, we studied the expression of VIP and its high affinity receptors (VPAC1 and VPAC2) in viable 
implantation sites. As shown in Fig. 1A,B, pregnancy significanlty increase the expression of VIP and their recep-
tors, VPAC1 and VPAC2. To assess if VPACs were functional, the implantation site explants were cultured in the 
absence/presence of VIP (100 nM) during 24 h and the expression of IL-17 and the transcription factor RORγ t were 
evaluated by RT-PCR. As an additional control implantation sites from CBA/J females after mating with BALB/c 
male at the same gestational age were used. Figure 1C,D, show that the treatment with VIP in vitro, significantly 
reduced IL-17 and RORγ t expression at the implantation sites. In fact, in those cultures performed in the absence 
of VIP, CBA/J × DBA/2 implantation sites displayed higher IL-17 and RORγ t expression compared with those 
in the control mating cultured under the same conditions. The present results show that implantation sites of 
CBA/J × DBA/2 mating have a functional VIP/VPAC system and also suggest that they display an exacerbated 
Th17 profile in comparison with the control that can be modulated in vitro by VIP.
In vivo VIP treatment increases the number of viable implantation sites and improves their 
asymmetric distribution. This pregnancy model with high resorption rates enables the evaluation of an 
immunomodulatory treatment and the study of different end points of pregnancy outcome as well as the isolation 
of implantation sites for further analysis. Therefore, CBA/J × DBA/2 female were treated in vivo with an intra-
peritoneal injection of VIP (2 nmol/mouse) or PBS (as control) in the early post-implantation period (at 6.5 day 
of gestation).
Figure 2A shows that VIP treatment significantly increased the number of viable implantation sites (day 8.5) 
in comparison with PBS-treatment, while did not modulate the number of sites with resorption. In addition, an 
improvement in the asymmetric distribution of implanted embryos was observed (Fig. 2B).
VIP treatment decreases RORγt while increases tolerogenic mediators expression at the 
implantation sites. In line with the previous results, we analyzed whether VIP in vivo treatment could 
modulate the immune microenvironment at the implantation sites. CBA/J × DBA/2 pregnant mice were treated 
in vivo with VIP or PBS, as described, and at day 8.5 the implantation sites were obtained and Foxp3/RORγ t 
expression ratio was evaluated by RT-PCR. Figure 3A shows that VIP treatment induced a significant decrease in 
RORγ t expression, implying that the Treg/Th17 ratio is increased.
Moreover, we investigated TGF-β and PPARγ expression, on the knowledge that TGF-β is not only a 
pro-implantatory mediator but it is also associated with suppressor functions; and that PPARγ increased expres-
sion and/or activity is essential for the acquisition of alternative activation in macrophages27,28. Figure 3B shows 
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that VIP treatment increased the expression of both tolerogenic markers, suggesting that VIP treatment induces 
a local tolerogenic microenvironment that would increase the number of viable embryos.
VIP treatment increases maternal macrophage efferocytosis. The constitution of the 
maternal-placental interface involves apoptosis of trophoblast cells, smooth muscle and endothelial cells that, 
in turn, requires an immediate clearance of apoptotic cells by macrophages and their activation in an alternative 
profile (to prevent a deleterious inflammatory response)5,29. Hence, we first explored whether the treatment of 
CBA/J × DBA/2 pregnant mice with VIP could modulate the efferocytic ability of maternal macrophages using 
two complementary approaches: the efferocytosis of apoptotic thymocytes and of latex beads.
For the first approach, the efferocytosis of apoptotic thymocytes, maternal macrophages were recovered at day 
8.5 after in vivo treatment with VIP, as previously described, and were co-cultured with syngeneic thymocytes 
induced to apoptosis. After, 30, 60, 90 and 120 min cells were stained with Hematoxilin–Eosin and analyzed by 
microscopy. As describes Fig. 4A, VIP treatment significantly increased the % of efferocytosis after 60 and 90 min 
of incubation with apoptotic thymocytes. This was accompained by a signficant increase in the phagocytic index 
(Fig. 4B). Figure 4C shows representative microphotographs of macrophages recovered from pregnant CBA/J 
treated with PBS or VIP after apoptotic thymocytes engulfment.
With the second approach, we could observe that the in vitro treatment with VIP increased the phagocytosis of 
latex beads by maternal macrophages, strongly suggesting that the increase in the efferocytosis observed in peri-
toneal macrophages was due to a direct effect of the peptide when injected to pregnant mice (Fig. 4D). Figure 4E 
shows a representative dot plot profile previous and after the efferocytosis assay in absence or presence of VIP.
Figure 1. VIP/VPAC system at the feto-maternal interface in CBA/J × DBA/2 mating. Pregnant  
CBA/J ×DBA/2 females or CBA non pregnant mice were sacrificed at 8.5 day of gestation and implantation 
sites were obtained. (A) VIP and (B) VPAC receptors were evaluated by RT-PCR as described in Mat erial and 
Methods (C) Implantation site explants isolated from CBAxDBA or CBAxBALB/c matings were cultured in 
the absence/presence of VIP (100 nM) during 24 h and IL-17 and RORγ t were evaluated by RT-PCR. Bands 
were semi-quantified with ImageJ® and intensity expressed in arbitrary units (AU) relative to GAPDH. Values 
represent mean ± S.E.M of at least 3 experiments (Mann Whitney test *p < 0.05).
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VIP treatment modulates macrophage cytokine production. Finally, we evaluated whether VIP 
treatment in vivo modulates the profile of cytokines produced by maternal macrophages from CBA/J pregnant 
mice. Therefore, after the efferocytosis assay, macrophages from pregnant CBA/J mice treated with PBS or VIP 
were washed and remained in culture for additional 24 h, then supernatants were collected for ELISA determina-
tions and cells recovered for FACS analysis.
As shown in Fig. 5A, the control mice that were not treated with VIP had higher levels of IL-12 while the CBA/J 
group treated with VIP did not modulate IL-12 levels (Fig. 5A). The same pattern of secretion was observed for 
TNF-α (Fig. 5B). In contrast, VIP treatment increased the frequency of F4/80 + IL10+ cells even before the effe-
rocytosis assay, suggesting that VIP treatment might modulate maternal macrophages in vivo (Fig. 5C).
Discussion
Homeostasis maintenance at the feto-maternal interface is the result of multiple processes that occur at local and 
systemic levels which require several ongoing signals and checkpoints. Immune cells involved in the control of the 
early inflammatory response have a central role at the maternal-placental interface such as the activation of mac-
rophages in an alternative profile or M2 instead of the classical inflammatory profile or M15,17. In the present work, 
we analyzed the immunoregulatory role of VIP in the CBA/J × DBA/2 mating with high resorption rate associated 
with a failure in the tolerogenic maternal response. The present results provide new data on the in vivo treatment 
with VIP, which prevents embryo resorption and improves pregnancy end points evidenced as an increase in the 
number of viable embryo with a symmetric distribution in the uterine horns.
The ability of VIP to improve pregnancy outcome is based in its immunomodulatory effects observed not only 
in the in vitro treatment of the implantation site explants with VIP but also in the in vivo treatment of pregnant mice 
at the early post implantation period. On the one hand, VIP decreased the Th17 response reflected by a reduction in 
IL-17 and RORγ expression after in vitro and in vivo treatments. This effect was accompained by an increase in the 
expression of immuno suppressor modulators as TGF-β and PPARγ at the implantation sites. On the other hand, 
Figure 2. In vivo VIP treatment increases the number of viable implantation sites and improves the 
asymmetric distribution. CBA/J × DBA/2 females were treated in vivo with VIP (2 nmol/mouse) or PBS i.p. 
at day 6.5 of gestation. At d8.5 females were sacrificed and (A) number of viable implantation sites and (B) the 
asymmetric distribution of implanted embryos were evaluated as described in Material and Methods. Values 
are media ± S.E. of viable sites counted in 8 mice (control group), 18 mice (CBAxDBA, PBS group) and 15 mice 
(CBAxDBA, VIP group).
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VIP modulated the efferocytosis of macrophages evaluated by two complementary approaches, the efferocytosis 
of latex beads and of apoptotic thymocytes. In addition, VIP treatment in vivo increased the frequency of F4/80+ 
IL-10-producing cells suggesting their activation in an alternative profile.
VIP immunomodulatory effect has been observed in the NOD mice, evidenced by the induction IL-10, TGF-β 
and Foxp3 expression at the implantation sites. In addition, implantation sites undergoing resorption processes 
showed lower VIP expression along with a lower expression of these cytokines and the transcription factor Foxp3, 
higher prostaglandin synthesis and higher expression of IL-17 and RORγ t12,30.
Recently, Obermajer et al. demonstrated the conversion of Th17 cells into Treg by which mesenchymal stem cells 
induced myeloid-derived immunosuppressive cells that mediate operational transplant tolerance. They demon-
strated that RORγ is a common factor in the differentiation of Treg and Th17 cells in mice, and the identification 
of IL-17A + Foxp3+ cells that then converts into a IL-17A-Foxp3+ cell strongly argues for direct conversion 
of Th17 cells into Treg cells31. Here, in the CBAxDBA model, we show that VIP treatment decreased RORγ and 
slightly increase Foxp3 expression. However, whether this new mechanism of immune regulation operates at the 
feto-maternal interface is still an open question.
With respect to the distribution of intrauterine embryo implantation sites, in most mammalian species shows 
remarkably constant patterns. In rodents, embryos implant evenly along the uterine horns and the disruption of 
these patterns can have adverse effects on pregnancies. Chen Q. et al., describe diverse molecular factors, such as 
steroid hormone signaling, lipid signaling, adrenergic signaling, developmental genes, ion/water channels, and 
potentially embryonic signaling are actively involved in intrauterine embryo distribution32; even VIP treatment 
improve symmetric distribution it will be interesting to investigate VIP efects on this potential mediators.
Regarding macrophage phenotypes, the classification is useful but represents an over simplification due to their 
substantial plasticity programming during the course of an inflammatory response, with markers and functions 
readily altered by external signals.
Figure 3. VIP treatment increases the Treg/Th17 ratio and the expression of tolerogenic mediators at the 
implantation sites. CBA/J × DBA/2 pregnant mice were treated in vivo with 2 nmol/mouse VIP or PBS i.p. at 
day 6.5 and the implantation sites were obtained at day 8.5. (A) Foxp3 and RORγ t expression and (B) TGF-β 
and PPARγ expression were evaluated by RT-PCR. Bands were semi-quantified with ImageJ® and intensity 
expressed in arbitrary units (AU) relative to GAPDH. Values represent mean ± S.E.M of at least 3 experiments 
(Mann Whitney test *p < 0.05).
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The activation of macrophages in an alternative profile has been associated with enhanced efferocytosis of apop-
totic cells preventing the release of intracellular contents that can contribute to inflammation and autoimmunity33. 
Collectively, these macrophages exhibit increased expression and/or activity of the nuclear receptors, PPARγ and 
PPARδ , essential to their acquisition of alternative activation profile, associated with increased levels of arginase, 
certain receptors and anti-inflammatory cytokines27,28.
Figure 4. VIP treatment increases the maternal macrophage efferocytosis ability. Peritoneal macrophages 
from CBA/J × DBA/2 females were recovered at 8.5 day of gestation and cultured with syngeneic thymocytes 
induced to apoptosis in the absence or presence of VIP (10 nM). After, 30, 60, 90 and 120 min cells were 
stained with Hematoxilin–Eosin and the (A) % of efferocytosis and (B) the phagocytic index were analyzed by 
microscopy. (C) Representative images of macrophages recovered from pregnant CBA/J treated with PBS or 
VIP after apoptotic thymocytes engulfment. (D) Maternal peritoneal macrophages were recovered at day 8.5 
after in vivo treatment with VIP or PBS and cultured with with latex-beads-FITC conjugated. After 90 min the 
percentage of efferocytosis was quantified by FACS analysis. (E) Representative dot plot profile previous and 
after the efferocytosis assay in absence or presence of VIP.
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Here we observed that in vivo VIP treatment improves efferocytosis evaluated by two complementary 
approaches, the use of latex beads and apoptotic thymocytes. Moreover, we also observed an increased expression 
of TGF-β and PPARγ at the implantation sites.
In this sense, in a murine model of chronic granulomatous disease (CGD), which exhibits chronic inflammation 
and mild autoimmunity, macrophages maintain a pro-inflammatory profile associated with an impaired efferocytic 
ability and decreased expression of PPARγ 34,35. In fact, the treatment with a PPARγ agonist in this mouse model 
of CGD, resolved prolonged zymosan-induced inflammation reflected by enhanced efferocytosis, and increased 
TGF-β and IL-10 production, highlighting a direct association between PPARγ increased expression and improved 
efferocytosis34. The macrophage PPARγ activation, increased efferocytic surface receptors and secretion of the 
bridge molecules, then enhanced efferocytic ability and the suppression of inflammation36.
These results also agree with previous data showing that VIP contributes to the switch of peritoneal macrophage 
predominant profile from an ‘inflammatory’ to a ‘regulatory’ phenotype at early pregnancy stages with increased 
production of IL-1037.
The cellular mechanisms that participate in VIP effect may involve multiple cells among which decidual cells 
and macrophages targeted by the peptide could contribute to a suitable immune tolerant microenvironment. Here, 
we show that the in vivo shift from inflammation to a pro-resolving state could be attributed, at least in part, to 
macrophages switching their programming in response to the changing milieu, suggesting that this peptide might 
be crucial to local homeostasis control at feto-maternal interface immunosuppressant mediators for adequate 
fetal growth.
Methods
Mice matings and treatment. An immunological model of exacerbated inflammation was represented by 
the mating combination CBA/J × DBA/2 and the combination CBA/J x BALB/c was used as a normal allogenic 
pregnancy (control mating). Mice were bred and maintained on a 12:12 h light–dark schedule in the Central 
Animal Care facility at the School of Exact and Natural Sciences, University of Buenos Aires (FCEyN-UBA).
Two-month-old CBA/J females were paired with BALB/c or DBA/2 males, checked daily for vaginal plugs and 
separated once mated. The day of the vaginal plug was considered as day 0.5 of pregnancy. The animals included in 
Figure 5. VIP treatment modulates macrophage cytokine production After the efferocytosis assay, 
macrophages from pregnant CBA/J mice treated with PBS or VIP (2 nmol/mouse) were washed and 
remained in culture for additional 24 h, then supernatants were collected and (A) IL-12 and (B) TNF-α 
were quantified by ELISA. (C) Cells were recovered and the frequency of F4/80 + IL-10+ analyzed by FACS. 
The left pannel shows representative dot plot with the frequency of of F4/80 + IL-10 from famele treated in vivo 
with PBS or VIP, previous and after the efferocytosis assay.
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the first part of the study received no treatment. In the second part of the study, pregnant CBA/J females mated with 
DBA/2 or BALB/c were treated with phosphate-buffered saline (PBS) intraperitoneally or with VIP (2 nmol/mouse) 
at day 6.5 of gestation. Pregnant females were killed at day 8.5 of gestation. All studies were conducted according 
to standard protocols and were approved by the Animal Care and Use Committee of the School of Sciencies, 
University of Buenos Aires. An asymmetry function was used to assess the effect of VIP on the distribution of 
impanted embryos along the horns, taking into account the number of embryo and the distance in each horn.
Uterus and implantation site isolation for functional studies. Pregnant uteri were carefully dissected 
at day 8.5 of pregnancy and implantation sites were defined as previously described37 and isolated for cytokine 
and transcription factors measurement23. Explants of implantation sites (inlcuded placenta, decidua and meso-
metrial lymphoied aggregate of pregnacy, MLAp tissue) were excised, embryos discarded and tissues were incu-
bated at 37 °C and 5%CO2 with VIP (100 nM) (Polypeptide labs, France) or not. Sites with viable embryos and 
sites with incipient resorption processes at gestational day 8.5 were assessed under magnifying glass, quantified 
to calculate resorption rate and photographed to show embryo distribution along horns among other gestation 
outcome signs as previously described12,23.
VIP/VPAC, Foxp3, RORγt and pro/anti inflammatory mediator detection. The expression of VIP 
and VPAC receptors, transcription factors and pro/anti inflammatory mediators was determined by RT-PCR. 
Briefly, total RNA was isolated following manufacturer recommendations with Trizol reagent (Life Technologies, 
Grand Island, NY, USA), cDNAs were generated from 1 ug or RNA using a MMLV reverse transcriptase, RNAsin 
RNAse inhibitor and oligodT kit (Promega Corporation, Madison, WI, USA) and stored at − 20 °C for batch 
analysis. The sample volume was increased to 25 ul with the solution containing 50 mM KCl; 10 mM Tris (pH 
8.3); 1.5 mM MgCl2; 0.1 mM forward and reverse primers of VIP, VPAC1, VPAC2, TGF-β , IL-17, PPRγ , Foxp3, 
RORγ T and GAPDH as internal control (described in Table 1) and 1 U Taq polymerase in a DNA Thermocycler 
(PerkinElmer/Cetus, Boston, MA, USA). PCR products were electrophoresed through a 2% ethidium 
bromide-stained agarose gel, visualized by transillumination and scanned. Densitometry was performed using 
ImageJ 1.47 software (NIH, USA) and results expressed as arbitrary units normalized to GAPDH expression. 
Each assay included a DNA minus control and a standard curve performed with serial dilutions of control cDNA.
Peritoneal macrophages isolation. Macrophages were obtained from pregnant CBA/J × DBA/2 mice at 
day 8.5, treated with PBS or VIP at day 6.5. The peritoneal cavity was washed with ice-cold HANKS as reported38 
were resuspended in RPMI 10% fetal calf serum (FCS) (Natocor Life Technologies, MD) and seeded in 24-well 
plates (Corning Glass, Corning, NY) at 5 × 105 cells/well. After incubation at 37 °C for 2 h, monolayers (> 95% 
macrophages by F4/80 flow cytometry staining) were used for phagocytosis assays.
Efferocytosis assays. To evaluate the efferocytosis ability we used two complementary approaches, the 
phagocytosis of latex beads-FITC and of apoptotic thymocytes.
Efferocytosis of latex beads-FITC. Peritoneal macrophages recovered from CBA/J × DBA/2 female at 8.5 day of 
gestation were cultured with latex beads (1–3 μ m) FITC-conjugated in the absence or presence of VIP (10 nM) in 
a 1:100 ratio (macrophage:beads). Incubations were performed at 37 °C with 5% CO2 in 24-well plates and after 
90 min macrophages were recovered by Triple® (Gybco, Invitrogen, Argentina) and the percentage of efferocytosis 
was quantified by FACS analysis. Results are expressed as % of FITC+ cells.
Efferocytosis of apoptotic thymocytes. Thymocytes were obtained from syngeneic mice of 21 days of age, were 
thoroughly washed and induced to apoptosis with 100 nM dexamethasone for 4 h at 37 °C38. Then macrophages 
were co-cultured with syngeneic thymocytes previously induced to apoptosis (ratio 1:5 macrophage: thymocytes). 
Incubations were run at 37 °C on coverslips placed inside 24-well plates for the indicated times (30, 60, 90 and 
120 min), then stained with Hematoxilin–Eosin and analyzed by microscopy. Results are expressed as the % of 
efferocytosis and the phagocytic index determination representing the number of apoptotic bodies phagocytized 
by each macrophage38.
Cytokine quantification. After the efferocytosis assay, macrophages from pregnant CBA/J females treated 
with PBS or VIP were washed and remained in culture for additional 24 h and then supernatants were collected 
Primers Forward Reverse
GAPDH TGATGACATCAAGAAGGTGGTGAAG TCCTTGGAGGCCATGTAGGCCAT
VIP TTCACCAGCGATTACAGCAG TCACAGCCATTTGCTTTCTG
VPAC1 GTGAAGACCGGCTACACCAT TGAAGAGGGCCATATCCTTG
VPAC2 GTGAAGACCGGCTACACCAT TGAAGAGGGCCATATCCTTG
PPARγ ATC TAC ACG ATG CTG GC GGA TGT CCT CGA TGG
TGF-β GACTCTCCACCTGCAAGACCA TTGGGGGACTGGCGAGCCTT
Foxp3 GGCCCTTCTCCAGGACAGA GCTGATCATGGCTGGGTTGT
IL-17 CTCCAGAAGGCCCTCAGACTAC AGCTTTCCCCTCCGCATTGACACAG
RORγ t CACGGCCCTGGTTCTCAT CAGATGTTCCACTCTCCTCTTCTCT
Table 1.  Primers used in RT-PCR assays. Oligonucleotide primers were designed using the online tool 
Primer3® (Whitehead Institute for Biomedical Research).
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for cytokine determination. Cytokines were also evaluated before the efferocytosis assay in both groups of mice 
under study. ELISA for TNF-α and IL-12 (eBiosciences, USA) were performed according to the manufacturer’s 
protocols. The limits of detection were 8 pg/ml for TNF-α and 4 pg/ml for IL-12. Results were expressed in pg/ml.
Flow-cytometric analysis. Intracellular staining for IL-10 detection. IL-10 production was quantified in 
macrophages of pregnant CBA/J females after in vivo treatment with PBS or VIP before and after efferocytosis. 
In the last 4 h of the assay, Stop Golgi (BD, Pharmigen, San José, CA, USA) was added to the culture to promote 
IL-10 intracellular accumulation. Then macrophages were recovered and after washing, cells were stained with 
anti-F4/80-FITC mAb for 30 min, fixed with Cytofix/cytoperm (BD, Pharmigen, San José, CA, USA) at room 
temperature and incubated for 30 min with anti-IL10-PE mAb (eBiosciece, USA).
Ten thousand events were acquired in a FACSAria cytometer and results were analyzed using the FlowJo soft-
ware. Negative control samples were incubated in parallel with an irrelevant isotype-matched antibody. Results 
for positive cells are expressed as a percentage of F4/80 + IL-10+ cells.
Statistical analysis. Statistical significance of differences was determined by the two-tailed t test for inde-
pendent populations and Student’s t test for parametric analysis. When multiple comparisons were necessary, 
the Student-Newman-Keuls test was used after analysis of variance. For in-vivo treatment experiments, the 
Mann-Whitney Test was used. Statistical significance was defined as p < 0.05, using the GraphPad Prism6 soft-
ware (GraphPad, San Diego, CA, USA).
References
1. Dekel, N., Gnainsky, Y., Granot, I. & Mor, G. Inflammation and implantation. Am. J. Immunol. 63, 17–21 (2010)
2. Weiss, G., Goldsmith, L. T., Taylor, R. N., Bellet, D. & Taylor, H. S. Inflammation in reproductive disorders. Reprod Sciences 16, 
216–229 (2009).
3. Gomez-Lopez, N., Guilbert, L. J. & Olson, D. M. Invasion of the leukocytes into the fetal-maternal interface during pregnancy. 
J. Leuk. Biol. 88, 625–633 (2010).
4. Mor, G. & Cardenas, I. The immune system in pregnancy: a unique complexity. Am. J. Reprod. Immunol. 63, 425–433 (2010).
5. Nagamatsu, T. & Schust, D. J. The contribution of macrophages to normal and pathological pregnancies. Am. J. Reprod. Immunol. 
63, 460–471 (2010).
6. Salamone, G. et al. Trophoblast cells induce a tolerogenic profile in dendritic cells. Hum. Reprod. 27, 2598–2606 (2012).
7. Teles, A. et al. Origin of Foxp3(+ ) cells during pregnancy. Am J Clin Exp Immuno 2, 222–233 (2013).
8. Pérez Leirós, C. & Ramhorst, R. Tolerance induction at the early maternal-placental interface through selective cell recruitment and 
targeting by immune polypeptides. Am. J. Reprod. Immunol. 69, 359–368 (2013).
9. Yoshinaga, K. Progesterone and Its Downstream Molecules as Blastocyst Implantation Essential Factors. Am. J. Reprod. Immunol. 4, 
117–128 (2014).
10. Robertson, S. A., Prins, J. R., Sharkey, D. J. & Moldenhauer, L. M. Seminal fluid and the generation of regulatory T cells for embryo 
implantation. Am. J. Reprod. Immunol. 69, 315–330 (2013).
11. Fraccaroli, L. et al. Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental-maternal 
leucocyte interaction impair the maternal tolerogenic response. Clin.Exp. Immunol. 170, 310–320 (2012).
12. Hauk, V. et al. Vasoactive intestinal peptide induces an immunosuppressant microenvironment in the maternal-fetal interface of 
non-obese diabetic mice and improves early pregnancy outcome. Am .J. Reprod. Immunol. 71, 120–130 (2014).
13. Santner-Nanan, B. et al. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy 
but not in preeclampsia. J. Immunol. 183, 7023–7030 (2009).
14. D’Addio, F. et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol. 1, 4530–4541 
(2011).
15. Abad, C., Tan, Y. V., Cheung-Lau, G., Nobuta, H. & Waschek, J. A. VIP deficient mice exhibit resistance to lipopolysaccharide induced 
endotoxemia with an intrinsic defect in proinflammatory cellular responses. PLoS One 7, e36922 (2012).
16. Mjosberg, J., Berg, G., Jenmalm, M. C. & Ernerudh, J. FOXP3+ regulatory T cells and T helper 1, T helper 2, and T helper 17 cells in 
human early pregnancy decidua. Biol. Reprod. 82, 698–705 (2009).
17. Mantovani, A., Biswas. S. K., Galdiero, M. R., Sica, A. & Locati, M. Macrophage plasticity and polarization in tissue repair and 
remodelling. J Pathol. 229, 176–185 (2013).
18. Fest, S. et al. Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy. Am J Reprod Immunol. 57, 
55–66 (2007).
19. Delgado, M., Munoz-Elias, E. J., Gomariz, R. P. & Ganea, D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating 
polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory 
factor 1 activation. J. Iimmunol 162, 4685–4696 (1999).
20. Gomariz, R. P. et al. Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides 28, 1825–1832 (2007).
21. Gonzalez-Rey, E., Anderson, P. & Delgado, M. Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune 
therapy. Annals Rheum. Dis. 66 Suppl 3, iii70–76 (2007).
22. Jimeno, R. et al. Effect of VIP on the balance between cytokines and master regulators of activated helper T cells. Immunol. Cell Biol. 
90, 178–186 (2012).
23. Roca, V. et al. Potential immunomodulatory role of VIP in the implantation sites of prediabetic nonobese diabetic mice. Reproduction 
138, 733–742 (2009).
24. Zenclussen, A. C. et al. Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-
induced CD4+ CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am. J. Pathol. 166, 811–822 (2005).
25. Clark, D. A., Chaouat, G., Arck, P. C., Mittruecker, H. W. & Levy, G. A. Cytokine-dependent abortion in CBA x DBA/2 mice is 
mediated by the procoagulant fgl2 prothrombinase J. Immunol. 15, 545–549 (1998).
26. Girardi, G., Yarilin, D., Thurman, J. M., Holers, V. M. & Salmon, J. E. Complement activation induces dysregulation of angiogenic 
factors and causes fetal rejection and growth restriction. J. Exp. Med. 203, 2165–2175 (2006).
27. Bouhlel, M. A. et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory 
properties. Cell Metab. 6, 137–143 (2007).
28. Odegaard, J. I. et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447, 
1116–1120 (2007).
29. Racicot, K., Kwon, J.-Y., Aldo, P., Silasi, M. & Mor, G. Understanding the Complexity of the Immune System during Pregnancy. Am. 
J. Reprod. Immunol. 72, 107–116 (2014).
30. Roca, V. et al. Reduced nitric oxide synthase and cyclo-oxygenase activity in the uterus of non-obese diabetic mice. Reproduction 
132, 931–938 (2006).
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:18633 | DOI: 10.1038/srep18633
31. Obermajer, N. et al. Conversion of Th17 into IL-17A(neg) regulatory T cells: a novel mechanism in prolonged allograft survival 
promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy. J.Immunol. 193, 4988–4999 (2014).
32. Chen, Q. et al. Navigating the site for embryo implantation: Biomechanical and molecular regulation of intrauterine embryo 
distribution. Mol. Asp. Med. 34, 1024–1042 (2013).
33. Schif-Zuck, S. et al. A. Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and 
glucocorticoids. Eur. J. Immunol. 41, 366–379 (2011).
34. Fernandez-Boyanapalli, R. et al. PPARgamma activation normalizes resolution of acute sterile inflammation in murine chronic 
granulomatous disease. Blood 116, 4512–4522 (2010).
35. Fernandez-Boyanapalli, R. F. et al. Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed 
by phosphatidylserine-dependent production of IL-4. Blood 113, 2047–2055 (2009).
36. Korns, D., Frasch, S. C., Fernandez-Boyanapalli, R., Henson, P. M. & Bratton, D. L. Modulation of macrophage efferocytosis in 
inflammation. Fron.Immunol. 2, 57. (2011)
37. Pang S. In The Guide to Investigation of Mouse Pregnancy (ed. Croy, A.) 21–42 (Elsevier Inc., 2014).
38. Larocca, L. et al. Modulation of macrophage inflammatory profile in pregnant nonobese diabetic (NOD) mice. Mol. Cell. Endocrinol. 
333, 112–118 (2011).
Acknowledgements
This study was supported by grants to RR and CPL (CONICET PIP 0602/12, UBACyT 2014-2017 and 2012-2015 
from University of Buenos Aires and PICT 0144/11 and PICT 1632/13 from ANPCyT).
Author Contributions
C.P.L. and R.R. designed the study, supervised the experimental work and wrote the manuscript. L.G. and G.C. 
carried out all the experiments with the mice models. L.F. and V.H. performed the efferocytosis assays. M.V. carried 
out the cytokine quantification and E.G. helped with RT-PCRs data analysis and interpretation. C.P.L. and R.R. 
supervised the whole study. All authors read and approved the final manuscript.
Additional Information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Gallino, L. et al. VIP treatment prevents embryo resorption by modulating efferocytosis 
and activation profile of maternal macrophages in the CBAxDBA resorption prone model. Sci. Rep. 6, 18633; 
doi: 10.1038/srep18633 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
